CLBIO logo

Corline Biomedical AB Stock Price

OM:CLBIO Community·SEK 393.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

CLBIO Share Price Performance

SEK 15.35
5.79 (60.56%)
SEK 15.35
5.79 (60.56%)
Price SEK 15.35

CLBIO Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with slight risk.

4 Risks
1 Reward

Corline Biomedical AB Key Details

SEK 8.6m

Revenue

SEK 2.4m

Cost of Revenue

SEK 6.2m

Gross Profit

SEK 20.9m

Other Expenses

-SEK 14.7m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.57
72.51%
-171.37%
0%
View Full Analysis

About CLBIO

Founded
1991
Employees
12
CEO
Henrik Nittmar
WebsiteView website
www.corline.se

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company also provides medical devices, such as coated stents and coated ablation catheter. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.

Recent CLBIO News & Updates

Recent updates

No updates